Literature DB >> 28780410

Genome-wide transcriptome analysis of hippocampus in rats indicated that TLR/NLR signaling pathway was involved in the pathogenisis of depressive disorder induced by chronic restraint stress.

Yu Wang1, Huili Jiang1, Hong Meng2, Jun Lu1, Jing Li1, Xuhui Zhang1, Xinjing Yang1, Bingcong Zhao1, Yang Sun1, Tuya Bao3.   

Abstract

Data from clinical investigations and laboratory fundings have provided preliminary evidence for the effectiveness and safety of acupuncture therapy in depression. However, the mechanisms underlying the antidepressant response of acupuncture are not fully elucidated. To elucidate the potential effects of acupuncture for depression on the hippocampal genome-wide transcriptome at the molecular level, we evaluated the transcriptomic profile of depression rats under treatment of acupuncture, and fluoxetine. We identified a very significant effect of acupucture intervention, with 107 genes differentially expressed in acupuncture vs. model group; while 41 genes between fluoxetine vs. model group. Notably, the 54 differentially expressed genes between acupuncture and fluoxetine showed the significantly different effect between acupuncture and fluoxetine. Through GO (gene ontology) functional term and KEGG (kyoto encyclopedia of genes and genomes) pathway analysis, we identified that the upregulation of gene sets were related to inflammatory response, innate immunity and immune response. We found that toll-like receptor signalling pathway and NOD like receptor signalling pathway were associated with the function of inflammatory response, innate immunity and immune response. Importantly, acupuncture reversed the upregulation of gene sets that were related to inflammatory response, innate immunity and immune response (including toll-like receptor signalling pathway and NOD like receptor signalling pathway), which might be critical for the pathogenesis of depression and provide evidence for the antidepressive effects of acupuncture by regulating inflammatory response, innate immunity and immune response via toll-like receptor signalling pathway and NOD like receptor signalling pathway.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic restraint stress; Depressive disorder; Hippocampus; RNA-sequencing (RNA-seq); Transcriptome

Mesh:

Substances:

Year:  2017        PMID: 28780410     DOI: 10.1016/j.brainresbull.2017.07.021

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  5 in total

1.  Acupuncture Ameliorates Depressive Behaviors by Modulating the Expression of Hippocampal Iba-1 and HMGB1 in Rats Exposed to Chronic Restraint Stress.

Authors:  Lu Chen; Huili Jiang; Tuya Bao; Yu Wang; Hong Meng; Yang Sun; Pengfei Liu; Songxiao Quan; Wenshan Li; Simin Qi; Xiujun Ren
Journal:  Front Psychiatry       Date:  2022-06-06       Impact factor: 5.435

2.  m6A Regulator-Mediated RNA Methylation Modification Patterns are Involved in the Pathogenesis and Immune Microenvironment of Depression.

Authors:  Ye Wang; Xinyi Wang; Chenyi Yang; Wei Hua; Haiyun Wang
Journal:  Front Genet       Date:  2022-04-11       Impact factor: 4.772

3.  Mechanistic analysis of erectile dysfunction in a depression rat model.

Authors:  Zhi-Ming Hong; Zi-Long Chen; Jun-Long Feng; Sheng-Jie Wang; Jun-Feng Qiu; Yang-Ling Zeng; Quan Wang; Ji-Sheng Wang
Journal:  J Int Med Res       Date:  2022-05       Impact factor: 1.573

4.  Mechanisms underlying antidepressant effect of transcutaneous auricular vagus nerve stimulation on CUMS model rats based on hippocampal α7nAchR/NF-κB signal pathway.

Authors:  Jun-Ying Wang; Yue Zhang; Yu Chen; Yu Wang; Shao-Yuan Li; Yi-Fei Wang; Zi-Xuan Zhang; Jinling Zhang; Peijing Rong
Journal:  J Neuroinflammation       Date:  2021-12-17       Impact factor: 8.322

5.  Validity of chronic restraint stress for modeling anhedonic-like behavior in rodents: a systematic review and meta-analysis.

Authors:  Ye Mao; Yongkang Xu; Xia Yuan
Journal:  J Int Med Res       Date:  2022-02       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.